The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages 51-

  Alao, John P ^a   Sunnerhagen, Per ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; CAFFEINE; CGK 733; CYCLIN D1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN DEFECT; PROTEIN PHOSPHORYLATION;

EID: 70749094311     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-51     Document Type: Article

References (34)

1. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008, 9:616-627. 2663384, 18594563, 10.1038/nrm2450.
2. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759-769. 10.1038/nrm2514, 18813293.
3. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4:216-225. 10.1038/nrc1296, 14993903.
4. Sarkaria JN, Eshleman JS. ATM as a target for novel radiosensitizers. Semin Radiat Oncol 2001, 11:316-327. 10.1053/srao.2001.26030, 11677656.
5. Alao JP. The ATM regulated DNA damage response pathway as a chemo- and radiosensitization target. Expert Opinion on Drug Discovery 2009, 4:495-505.
6. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004, 64:9152-9159. 10.1158/0008-5472.CAN-04-2727, 15604286.
7. Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol 2005, 71:13-20. 10.1016/j.bcp.2005.09.029, 16293233.
8. Won J, Kim M, Kim N, Ahn JH, Lee WG, Kim SS, Chang KY, Yi YW, Kim TK. Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol 2006, 2:369-374. 10.1038/nchembio800, 16767085.
9. Bhattacharya S, Ray RM, Johnson LR. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal 2009, 21:509-522. 10.1016/j.cellsig.2008.12.003, 19136059.
10. Cruet-Hennequart S, Glynn MT, Murillo LS, Coyne S, Carty MP. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst) 2008, 7:582-596. 10.1016/j.dnarep.2007.12.012, 18289945.
11. Goldstein M, Roos WP, Kaina B. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol Appl Pharmacol 2008, 229:20-32. 10.1016/j.taap.2008.01.001, 18289623.
12. Yang XH, Shiotani B, Classon M, Zou L. Chk1 and Claspin potentiate PCNA ubiquitination. Genes Dev 2008, 22:1147-1152. 2335311, 18451105, 10.1101/gad.1632808.
13. Crescenzi E, Palumbo G, de Boer J, Brady HJ. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res 2008, 14:1877-1887. 10.1158/1078-0432.CCR-07-4298, 18347191.
14. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008, 76:947-957. 10.1016/j.bcp.2008.06.024, 18657518.
15. Kahlem P, Dorken B, Schmitt CA. Cellular senescence in cancer treatment: friend or foe?. J Clin Invest 2004, 113:169-174. 311442, 14722606.
16. Elmore LW, Di X, Dumur C, Holt SE, Gewirtz DA. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 2005, 11:2637-2643. 10.1158/1078-0432.CCR-04-1462, 15814644.
17. Marcotte R, Lacelle C, Wang E. Senescent fibroblasts resist apoptosis by downregulating caspase-3. Mech Ageing Dev 2004, 125:777-783. 10.1016/j.mad.2004.07.007, 15541772.
18. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005, 65:2795-2803. 10.1158/0008-5472.CAN-04-1270, 15805280.
19. Seluanov A, Gorbunova V, Falcovitz A, Sigal A, Milyavsky M, Zurer I, Shohat G, Goldfinger N, Rotter V. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol 2001, 21:1552-1564. 86701, 11238892, 10.1128/MCB.21.5.1552-1564.2001.
20. Wendt J, Radetzki S, von Haefen C, Hemmati PG, Guner D, Schulze-Osthoff K, Dorken B, Daniel PT. Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene 2006, 25:972-980. 10.1038/sj.onc.1209031, 16331277.
21. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006, 34:1685-1691. 1410911, 16556909, 10.1093/nar/gkl108.
22. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117:1440-1449. 1847538, 17431503, 10.1172/JCI31245.
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112. 10.1093/jnci/82.13.1107, 2359136.
24. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007, 6:24. 1851974, 17407548, 10.1186/1476-4598-6-24.
25. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000, 14:3102-3114. 317128, 11124803, 10.1101/gad.854900.
26. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997, 11:957-972. 10.1101/gad.11.8.957, 9136925.
27. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008, 8:714-724. 10.1038/nrc2401, 19143056.
28. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004, 10:8094-8104. 10.1158/1078-0432.CCR-04-1023, 15585645.
29. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008, 7:3355-3361.
30. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA 2002, 99:389-394. 117570, 11752408, 10.1073/pnas.012602599.
31. Hitomi M, Yang K, Stacey AW, Stacey DW. Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol 2008, 28:5478-5493. 2519724, 18606783, 10.1128/MCB.02047-07.
32. Nakai-Murakami C, Shimura M, Kinomoto M, Takizawa Y, Tokunaga K, Taguchi T, Hoshino S, Miyagawa K, Sata T, Kurumizaka H. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 2007, 26:477-486. 10.1038/sj.onc.1209831, 16983346.
33. Al-Minawi AZ, Saleh-Gohari N, Helleday T. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 2008, 36:1-9. 2248766, 17962301, 10.1093/nar/gkm888.
34. Yamauchi M, Oka Y, Yamamoto M, Niimura K, Uchida M, Kodama S, Watanabe M, Sekine I, Yamashita S, Suzuki K. Growth of persistent foci of DNA damage checkpoint factors is essential for amplification of G1 checkpoint signaling. DNA Repair (Amst) 2008, 7:405-417. 10.1016/j.dnarep.2007.11.011, 18248856.